Twin Capital Management Inc. Sells 94 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Twin Capital Management Inc. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 4,001 shares of the biopharmaceutical company’s stock after selling 94 shares during the quarter. Twin Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,514,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Ronald Blue Trust Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 18.8% during the 3rd quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 12 shares during the period. Drive Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 4.0% during the 4th quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 12 shares during the period. Cassia Capital Partners LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 2.3% during the 3rd quarter. Cassia Capital Partners LLC now owns 589 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 13 shares during the period. Sutton Wealth Advisors Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 13 shares during the period. Finally, Clearview Wealth Advisors LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 1.5% during the 4th quarter. Clearview Wealth Advisors LLC now owns 855 shares of the biopharmaceutical company’s stock worth $751,000 after buying an additional 13 shares during the period. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on REGN shares. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. StockNews.com upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 12th. Cantor Fitzgerald reiterated a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday. BMO Capital Markets upped their target price on shares of Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Finally, Bank of America increased their price objective on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $976.41.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN traded down $3.53 during mid-day trading on Thursday, reaching $897.66. 183,903 shares of the company were exchanged, compared to its average volume of 491,315. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $998.33. The company has a fifty day moving average of $955.19 and a 200 day moving average of $890.52. The company has a quick ratio of 4.94, a current ratio of 5.69 and a debt-to-equity ratio of 0.10. The stock has a market cap of $98.53 billion, a PE ratio of 25.93, a PEG ratio of 2.58 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter last year, the firm earned $10.96 EPS. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.58 EPS for the current fiscal year.

Insider Activity

In other news, EVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at approximately $46,203,239.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the completion of the sale, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The disclosure for this sale can be found here. In the last quarter, insiders have sold 13,729 shares of company stock valued at $13,124,641. 8.83% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.